3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Breast Neoplasms
15
Leukemia
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Leukemia, Myeloid, Chronic-Phase
10
Recurrence
8
Prostatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Lung Neoplasms
7
Neoplasm Metastasis
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Melanoma
5
Burkitt Lymphoma
5
Pancreatic Neoplasms
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Blast Crisis
4
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Neoplasms
3
Lymphoma
3
Gliosarcoma
3
Sarcoma
2
Salivary Gland Neoplasms
2
Rhabdomyosarcoma
2
Rectal Neoplasms
2
Polycythemia Vera
2
Oligodendroglioma
2
Multiple Myeloma
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
Nivolumab
11
Ipilimumab
6
linrodostat
4
relatlimab
3
Pemetrexed
2
tislelizumab
1
regorafenib
1
ralimetinib
1
p38 Mitogen-Activated Protein Kinases
1
mirdametinib
1
gedatolisib
1
figitumumab
1
efatutazone
1
abemaciclib
1
Vorinostat
1
Tetanus Toxoid
1
Tamoxifen
1
Sunitinib
1
Ranitidine
1
Midazolam
1
LY2603618
1
LY2584702
1
Irinotecan
1
Gemcitabine
1
Fulvestrant
1
Dasatinib
1
Cyclophosphamide
1
Crizotinib
1
Cetuximab
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Cancer
×
Dasatinib
×
Clear all
NCT02750514
2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2
Terminated
295 enrolled
21 charts